New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
New Delhi [India], June 15 (ANI): The subject expert committee meeting that was scheduled today to discuss Serum Institute of India's (SII) indigenously developed Quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, has recommended regular market authorisation for above 9 to 26-year-old male and female, according to sources.
Pune (Maharashtra) [India], May 5 (ANI): Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
President of the 76th session of the UN General Assembly Abdulla Shahid has said he received the two doses of the Covishield vaccine manufactured in India He also added that a “large portion” of other countries around the world have also received India’s Covid-19 vaccine, Covishield. The Covishield vaccine, developed by AstraZeneca, is manufactured in […]